Safety and Efficacy of Stereotactic Cardiac Radio-Ablation for Ventricular Tachycardia in Patients at High Risk of Mortality

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Calum J. Redpath MBChB, MRCP, PhD , Andrew M. Crean MRCP FRCR, MPH , Pablo B. Nery MD , Girish M. Nair MBBS, MSc, FRCPC , Mehrdad Golian MD, MSc , Simon Hansom BSc, MBBS, MRCP (UK) , Connor Haberl MASc , Robert deKemp PhD , Phillip S. Cuculich MD , Clifford G. Robinson MD , Katie S. Lekx-Toniolo MCCPM, PhD , David Tiberi MD, FRCPC , Graham Cook MD, FRCPC
{"title":"Safety and Efficacy of Stereotactic Cardiac Radio-Ablation for Ventricular Tachycardia in Patients at High Risk of Mortality","authors":"Calum J. Redpath MBChB, MRCP, PhD ,&nbsp;Andrew M. Crean MRCP FRCR, MPH ,&nbsp;Pablo B. Nery MD ,&nbsp;Girish M. Nair MBBS, MSc, FRCPC ,&nbsp;Mehrdad Golian MD, MSc ,&nbsp;Simon Hansom BSc, MBBS, MRCP (UK) ,&nbsp;Connor Haberl MASc ,&nbsp;Robert deKemp PhD ,&nbsp;Phillip S. Cuculich MD ,&nbsp;Clifford G. Robinson MD ,&nbsp;Katie S. Lekx-Toniolo MCCPM, PhD ,&nbsp;David Tiberi MD, FRCPC ,&nbsp;Graham Cook MD, FRCPC","doi":"10.1016/j.cjco.2025.01.015","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Patients who have recurrent ventricular tachycardia (VT) despite receiving antiarrhythmic drugs (AADs), implantable cardioverter defibrillator placement, and catheter ablation (CA) are at significant risk of morbidity and mortality.</div></div><div><h3>Methods</h3><div>We offered completely noninvasive cardiac radio-ablation (CRA) on a “compassionate use” basis for patients who were unable or unwilling to undergo CA for recurrent VT despite their having received treatment with AADs and placement of an implantable cardioverter defibrillator. All patients who were referred to the CRA program were entered into a prospective registry and followed indefinitely thereafter.</div></div><div><h3>Results</h3><div>A total of 20 patients were referred for CRA, and 10 elected to undergo the treatment as outpatients. Ten patients declined CRA therapy, owing to fear of complications and/or logistic concerns relating to attending multiple hospital visits; they received escalated drug therapy. All patients who were referred to and were agreeable to CRA received CRA. No patients were excluded or were denied CRA by clinicians for any reason, and all patients were followed clinically. The VT burden decreased significantly, by &gt; 90% (both anti-tachycardia pacing and shocks), and 1 patient died of a cardiovascular cause at 1 year following a single CRA treatment of 25 Gy. One patient experienced steroid-responsive pneumonitis as an adverse event post-CRA (common terminology criteria for adverse events [CTCAE] grade 2). For the 10 patients who declined CRA, no appreciable reduction in VT occurred, despite their receipt of increasing dosages of AADs, and 5 patients died of cardiovascular causes within 1 year.</div></div><div><h3>Conclusions</h3><div>Noninvasive stereotactic CRA is well tolerated with good short-term efficacy for recurrent VT on a “compassionate use” basis. Prospective randomized controlled trials to determine the relative efficacy of CA vs CRA for VT are urgently required.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 5","pages":"Pages 545-554"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X25000435","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Patients who have recurrent ventricular tachycardia (VT) despite receiving antiarrhythmic drugs (AADs), implantable cardioverter defibrillator placement, and catheter ablation (CA) are at significant risk of morbidity and mortality.

Methods

We offered completely noninvasive cardiac radio-ablation (CRA) on a “compassionate use” basis for patients who were unable or unwilling to undergo CA for recurrent VT despite their having received treatment with AADs and placement of an implantable cardioverter defibrillator. All patients who were referred to the CRA program were entered into a prospective registry and followed indefinitely thereafter.

Results

A total of 20 patients were referred for CRA, and 10 elected to undergo the treatment as outpatients. Ten patients declined CRA therapy, owing to fear of complications and/or logistic concerns relating to attending multiple hospital visits; they received escalated drug therapy. All patients who were referred to and were agreeable to CRA received CRA. No patients were excluded or were denied CRA by clinicians for any reason, and all patients were followed clinically. The VT burden decreased significantly, by > 90% (both anti-tachycardia pacing and shocks), and 1 patient died of a cardiovascular cause at 1 year following a single CRA treatment of 25 Gy. One patient experienced steroid-responsive pneumonitis as an adverse event post-CRA (common terminology criteria for adverse events [CTCAE] grade 2). For the 10 patients who declined CRA, no appreciable reduction in VT occurred, despite their receipt of increasing dosages of AADs, and 5 patients died of cardiovascular causes within 1 year.

Conclusions

Noninvasive stereotactic CRA is well tolerated with good short-term efficacy for recurrent VT on a “compassionate use” basis. Prospective randomized controlled trials to determine the relative efficacy of CA vs CRA for VT are urgently required.

Abstract Image

立体定向心脏放射消融治疗死亡率高的室性心动过速的安全性和有效性
背景:尽管接受了抗心律失常药物(AADs)、植入式心律转复除颤器放置和导管消融(CA),但复发性室性心动过速(VT)患者的发病率和死亡率都很高。方法:我们在“同情使用”的基础上,对那些接受了AADs治疗和植入式心律转复除颤器的复发性VT患者不能或不愿接受心脏消融术(CRA)。所有转介到CRA项目的患者都进入了前瞻性登记,此后无限期随访。结果20例患者转介CRA, 10例患者选择门诊治疗。10名患者拒绝CRA治疗,原因是担心并发症和/或多次就诊的后勤问题;他们接受了升级的药物治疗。所有转介并同意CRA的患者均接受CRA。没有患者因任何原因被临床医生排除或拒绝CRA,所有患者均被临床随访。VT负荷量显著下降,约为1小时;90%(包括抗心动过速起搏和休克),1例患者在单次25 Gy的CRA治疗1年后死于心血管原因。一名患者在cra后出现类固醇反应性肺炎(不良事件的通用术语标准[CTCAE] 2级)。对于CRA下降的10例患者,尽管他们接受了AADs剂量的增加,但VT没有明显降低,5例患者在1年内死于心血管原因。结论无创立体定向CRA治疗复发性室速具有良好的耐受性和短期疗效。迫切需要前瞻性随机对照试验来确定CA与CRA治疗VT的相对疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CJC Open
CJC Open Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.30
自引率
0.00%
发文量
143
审稿时长
60 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信